News Releases

In this section of the ACME MediaRoom, you'll find our news releases. The releases are listed in chronological order and are archived by year.

Archives: Search / 2012 / 2011 / 2010 / 2009 / 2008 / 2007

May 9, 2012
Resverlogix Completes Dosing of RVX-208 in SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
Apr 23, 2012
Resverlogix' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials
Apr 19, 2012
Resverlogix Conference Call & Webcast to Announce Platform Mechanism of Action
Feb 8, 2012
Resverlogix to Present at The 14th Annual BIO CEO & Investor Conference
Jan 19, 2012
Resverlogix Enters Into Equity Distribution Agreement
Nov 29, 2011
Resverlogix Closes Equity Offering
Nov 28, 2011
Resverlogix Announces Full Enrollment of SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
Nov 23, 2011
Resverlogix Announces $17.5 million Equity Offering
Nov 15, 2011
Resverlogix Announces the Issuing of Patent Covering RVX-208
Nov 2, 2011
Resverlogix Commences Dosing in ASSURE a Phase 2b IVUS Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
Sep 27, 2011
Resverlogix Expands Phase 2b Program with the Commencement of Dosing in SUSTAIN
Sep 26, 2011
Resverlogix Activates Study Sites in ASSURE Phase 2b IVUS Trial for Atherosclerotic Plaque Regression
Sep 1, 2011
Resverlogix Presents Two Abstracts on Analysis of the Phase 2 ASSERT Clinical Trial at The ESC Congress 2011
Jun 28, 2011
Resverlogix Presents New Findings on RVX-208 at European Atherosclerosis Society
Jun 27, 2011
Resverlogix Announces New Data on Autoimmune Program featured at World Congress of Inflammation
Jun 23, 2011
Resverlogix Announces Dr. H. Bryan Brewer Joins Clinical Steering Committee
Jun 14, 2011
Resverlogix Closes Equity Offering
Jun 13, 2011
Resverlogix Launches Phase IIb ASSURE Trial for RVX-208 Cholesterol Transport Drug, Safety Data Completed and Filed
Jun 3, 2011
Resverlogix to Raise $12.6 Million
Jun 2, 2011
Resverlogix Announces Overnight Marketed Equity Offering
Jan 25, 2011
Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's Disease
Dec 13, 2010
Resverlogix Appoints Dr. Eldon R. Smith to Board of Directors
Nov 29, 2010
Successful ASSERT Trial Results in Resverlogix Filing New RVX-208 Patent
Nov 25, 2010
Resverlogix Notice of Conference Call & Webcast to Provide a Market Update
Nov 17, 2010
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session